By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Hemispherx Biopharma Inc. 

One Penn Center
1617 JFK Boulevard
Philadelphia  Pennsylvania  19103  U.S.A.
Phone: 215-988-0080 Fax: 215-988-1739


Company News
Hemispherx (HEB) Announces Major Breakthrough: Approval For Commercial Sale Of Rintatolimod (U.S. Tradename: Ampligen) To Treat Severe Cases Of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) In The Argentine Republic 8/23/2016 8:02:03 AM
Hemispherx (HEB) Forms Scientific Advisory Board To Provide Additional Scientific And Pharmaceutical Expertise 8/19/2016 6:49:56 AM
Hemispherx (HEB) Announces 1-for-12 Reverse Stock Split 8/18/2016 7:39:27 AM
Hemispherx (HEB) Announces Financial Results For The Six Months Ended June 30, 2016 8/16/2016 9:20:03 AM
Hemispherx (HEB) Conducts An Interview With The Wall Street Transcript 8/16/2016 9:08:44 AM
Hemispherx (HEB) Reaches Agreement With Avrio Biopharmaceuticals For The Accelerated Production Of Ampligen 7/27/2016 8:17:35 AM
Hemispherx (HEB) Announces First Shipment Of Rintatolimod (Ampligen) To Early Access Program In Europe 7/25/2016 8:50:24 AM
Hemispherx (HEB) Bolsters Manufacturing And Scientific Capabilities Through Key Consulting And Management Appointments 7/19/2016 8:18:19 AM
Hemispherx (HEB) Details Strategic Growth Plan, Transparency Commitment 7/14/2016 7:18:02 AM
Hemispherx (HEB) Updates The Status Of The Alferon Manufacturing Facility 7/11/2016 8:09:38 AM